How could the planned separation of Caremark affect Eli Lilly and Company?
Eli Lilly's market access may shift as CVS separates Caremark PBM CVS Health is planning to spin off its retail pharmacy business, CVS Pharmacy, into a new publicly traded company in the first half of 2028, separating it from the Aetna insurance unit and the Caremark prescription benefits division. This move dismantles the vertically integrated structure that previously allowed CVS to manage patient access and distribution across its businesses. Because CVS and Eli Lilly and Company already maintain a complex operational relationship involving formulary decisions and patient access, the separation of the PBM (Caremark) from the insurer (Aetna) could change how drug coverage is determined and how products reach patients.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
CVS Health initially announced a plan to spin off its retail pharmacy business into a new company, CVS Pharmacy, in the first half of 2028, separating it from Aetna and Caremark. However, the company later confirmed it is retaining both the Caremark pharmacy benefit management unit and the Aetna health insurance business.
The full event2independent outlets -
Caremark functions as the Pharmacy Benefit Manager (PBM), which is responsible for formulary decisions—determining which drugs are covered and at what cost. The reports note that CVS and Eli Lilly and Company engage in a complex operational relationship involving both market competition and strategic partnerships for patient access and distribution.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- CVS Health plans to spin off its retail pharmacy business into a new company called CVS Pharmacy in the first half of 2028.reporterherald.com
- The split will separate the retail pharmacy business from the Aetna insurance unit and Caremark prescription benefits division.reporterherald.com
- CVS and Eli Lilly and Company engage in a complex operational relationship involving both market competition (formulary decisions) and strategic partnerships for patient access and distribution.reporterherald.com
- The pharmacy and consumer wellness segment generated over $139 billion in revenue last year.reporterherald.com
Why it matters
The ability of a pharmaceutical company like Eli Lilly and Company to achieve market penetration and maximize revenue is heavily dependent on PBM decisions. PBMs, like Caremark, control formulary lists, which dictate whether a drug is covered by an insurer and at what level of cost-sharing for the patient. A change in the structure of the PBM—moving it from an integrated corporate unit to a standalone entity—could change the negotiating leverage and the criteria used for coverage decisions.
This move also occurs amid growing political pressure on large healthcare conglomerates regarding their reach into different businesses. The consolidation model, which allowed companies to turn expenses into revenue across their integrated system, is being challenged by lawmakers, making the structural separation of Caremark a significant industry development.
What we don't know yet
- Will the separation of Caremark lead to changes in how it negotiates drug prices with pharmaceutical manufacturers?
- How will the new, standalone CVS Pharmacy entity influence patient access to medications compared to the integrated model?
Is this still moving?
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- reporterherald.comWednesday
- investors.comWednesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.